Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial

Clinical Lung Cancer

Volumn 17, Issue 1, 2016, Pages 10-17.e1

  Chlebowski, Rowan T ^a   Wakelee, Heather ^b   Pettinger, Mary ^c   Rohan, Thomas ^d   Liu, Jingmin ^c   Simon, Michael ^e   Tindle, Hilary ^f   Messina, Catherine ^b   Johnson, Karen ^g   Schwartz, Ann ^h   Gass, Margery ⁱ   Wactawski Wende, Jean ^j  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ North American Menopause Society   (United States)

^j UNIVERSITY AT BUFFALO   (United States)

more..

Author keywords

Estrogen plus progestin; Lung cancer; Lung cancer mortality; Randomized trial; Women's Health Initiative

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CONTROLLED STUDY; DEMOGRAPHY; DISTANT METASTASIS; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; LUNG CANCER; MAJOR CLINICAL STUDY; MIDDLE AGED; OBSERVATIONAL STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; COMBINATION DRUG THERAPY; LUNG NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL RATE; WOMEN'S HEALTH;

AGED; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PROGESTINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE; WOMEN'S HEALTH;

EID: 84953362238     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2015.09.004     Document Type: Article

References (31)

1. R.T. Chlebowski, A.G. Schwartz, H. Wakelee, and et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomized controlled trial Lancet 374 2009 1243 1251
2. R.T. Chlebowski, G.L. Anderson, J.E. Manson, and et al. Lung cancer among postmenopausal women treated with estrogen alone in the Women's Health Initiative randomized trial J Natl Cancer Inst 102 2010 1413 1421
3. M.B. Schabath, X. Wu, R. Vassilopoulou-Sellin, and M.R. Spitz Hormone replacement therapy and lung cancer risk: a case-control analysis Clin Cancer Res 10 2004 113 123
4. A.G. Schwartz, A.S. Wenzlaff, G.M. Prysak, and et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non-small cell lung cancer in women J Clin Oncol 25 2007 5785 5792
5. C. Rodriguez, H. Spencer Feigelson, A. Deka, and et al. Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort Cancer Epidemiol Biomarkers Prev 17 2008 655 660
6. M. Kruezer, M. Gerken, J. Heinrich, and et al. Hormonal factors and risk of lung cancer among women? Int J Epidemiol 32 2003 263 271
7. C.S. Baik, G.M. Strauss, and D. Feskanich A prospective study of reproductive factors, hormone use, and risk of lung cancer in postmenopausal women J Clin Oncol 27 2009 abstract 1501
8. E. Taioli, and E.L. Wynder Re: Endocinre factors and adenocarcinoma of the lung in women J Natl Cancer Inst 86 1994 869 870
9. Y. Liu, M. Inoue, T. Sobue, and et al. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study Int J Cancer 117 2005 662 666
10. A.C. Pesatori, M. Carugno, D. Consonni, and et al. Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO) Br J Cancer 109 2013 1954 1964
11. Y. Yao, X. Gu, J. Zhu, and et al. Hormone replacement therapy in females can decrease the risk of lung cancer: a meta-analysis PLoS One 8 2013 e71236
12. J.A. Manson, R.T. Chlebowski, M.L. Stefanick, and et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials JAMA 310 2013 1353 1368
13. J.E. Rossouw, G.L. Anderson, R.L. Prentice, and et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
14. G.L. Anderson, M. Limacher, A.R. Assaf, and et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 29 2004 1701 1712
15. National Cancer Institute. Surveillance Epidemiology and End Results. Available at: http://www.seer.cancer.gov. Accessed: September 9, 2009.
16. N. Ferrara, and R.S. Kerbel Angiogenesis as a therapeutic target Nature 438 2005 967 974
17. O. Barnabas, H. Wang, and X.M. Gao Role of estrogen in angiogenesis in cardiovascular diseases J Geriatr Cardiol 10 2013 377 382
18. D.C. Marquez-Garban, H.W. Chen, L. Goodglick, and et al. Targeting aromatase and estrogen signaling in human non-small cell lung cancer Ann N Y Acad Sci 115 2009 194 205
19. J.M. Siegfried, and L.P. Stabile Estrogenic steroid hormones in lung cancer Semin Oncol 41 2014 5 16
20. R.T. Chlebowski, M.R. Palomares, L. Lillington, and et al. Recent implications of weight loss in lung cancer Nutrition 12 1996 S43 S47
21. R.M. Bremes, S. Sundstrom, U. Aasebo, et al. Norweigian Lung Cancer Study Group The value of prognostic factors in small cell lung cancer: results from a randomized multicenter study with minimum 5 year follow-up Lung Cancer 39 2003 303 313
22. International Early Lung Cancer Action Program Investigators Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer JAMA 296 2006 180 184
23. H.A. Wakelee, W. Wang, J.H. Schiller, et al. Eastern Cooperative Oncology Group Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group Trial 1594 J Thorac Oncol 1 2006 441 446
24. H. Ross, F.B. Oldham, and B. Bandstra Serum-free estradiol (E2) levels are prognostic in men with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC) and performance status (PS) J Clin Oncol 25 2007 15S ASCO Ann Proc
25. A.K. Ganti, A.E. Sahmoun, A.W. Panwalker, and et al. Hormone replacement therapy is associated with decreased survival in women with lung cancer J Clin Oncol 24 2006 59 63
26. O. Ayeni, and A. Robinson Hormone replacement therapy and outcomes for women with non-small cell lung cancer: can an association be confirmed? Curr Oncol 16 2009 21 25
27. B. Huang, H. Carloss, S.E. Wyatt, and et al. Hormone replacement therapy and survival from lung cancer in postmenopausal women in a rural population Cancer 115 2009 4167 4175
28. B. Ettinger, G.D. Friedman, T. Bush, and et al. Reduced mortality associated with long-term postmenopausal estrogen therapy Obstet Gynecol 87 1996 6 12
29. H. Katcoff, A.S. Wenzlaff, and A.G. Schwartz Survival in women with NSCLC: the role of reproductive history and hormone use J Thorac Oncol 9 2014 355 361
30. J. Clague, P. Reynolds, K.D. Henderson, and et al. Menopausal hormone therapy and lung cancer-specific mortality following diagnosis: the California Teachers study PLoS One 9 2014 e103735
31. S. Suissa Randomized trials built on sand: examples from COPD, hormone therapy, and cancer Rambam Maimonides Med J 3 2012 e0014